Kiromic BioPharma (NASDAQ:KRBP) Shares Down 15.4%

Kiromic BioPharma, Inc. (NASDAQ:KRBPGet Free Report) was down 15.4% during mid-day trading on Thursday . The stock traded as low as $2.75 and last traded at $2.75. Approximately 3,620 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 6,605 shares. The stock had previously closed at $3.25.

Kiromic BioPharma Trading Down 15.4 %

The firm has a 50-day moving average of $2.79 and a 200-day moving average of $1.98. The stock has a market capitalization of $4.24 million, a price-to-earnings ratio of -0.28 and a beta of 2.03.

Kiromic BioPharma (NASDAQ:KRBPGet Free Report) last released its earnings results on Friday, May 10th. The company reported ($1.00) earnings per share (EPS) for the quarter.

About Kiromic BioPharma

(Get Free Report)

Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.

Featured Articles

Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.